NEUROLOGIE PRO PRAXI / Neurol. praxi. 2024;25(3):192-196 / www.neurologiepropraxi.cz 196 HLAVNÍ TÉMA Refrakterní a super‑refrakterní status epilepticus 8. Ernst LD, Raslan AM, Wabulya A, et al. J Neurosurg. 2023:1-9. doi: 10.3171/2023. 4. JNS23367. Epub ahead of print. 9. Ferlisi M, Hocker S, Trinka E, et al. The anesthetic drug treatment of refractory and super‑refractory status epilepti‑ cus around the world: results from a global audit. Epilepsy Behav. 2019;101(pt B):106449. doi: 10.1016/j.yebeh.2019.106449. 10. Ferlisi M, Shorvon S. The outcome of therapies in refracto‑ ry and super‑refractory convulsive status epilepticus and re‑ commendations for therapy. Brain. 2012;135(Pt 8):2314-28. doi: 10.1093/brain/aws091. 11. Gilbert DL, Gartside PS, Glauser TA. Efficacy and morta‑ lity in treatment of refractory generalized convulsive status epilepticus in children: A meta‑analysis. J Child Neurol. 1999; 14(9):602-9. doi: 10.1177/088307389901400909. 12. Greiner HM, Tillema JM, Hallinan BE, et al. Corpus calloso‑ tomy for treatment of pediatric refractory status epilepticus. Seizure. 2012;21(4):307-9. doi: 10.1016/j.seizure.2012. 01. 010. 13. Hawkes MA, Eliliwi M, Wijdicks EFM. The Origin of the Burst‑Suppression Paradigm in Treatment of Status Epilep‑ ticus. Neurocrit Care. 2023 Nov 3. doi: 10.1007/s12028-02301877-0. Epub ahead of print. 14. Hirsch LJ, Gaspard N, van Baalen A, et al. Proposed con‑ sensus definitions for new‑onset refractory status epilep‑ ticus (NORSE), febrile infection‑related epilepsy syndrome (FIRES), and related conditions. Epilepsia. 2018;59(4):739-744. doi: 10.1111/epi.14016. 15. Hocker S. Systemic complications of status epilepticus – An update. Epilepsy Behav. 2015;49:83-7. doi: 10.1016/j.ye‑ beh.2015. 04. 024. 16. Höfler J, Rohracher A, Kalss G, et al. (S)-Ketamine in Refractory and Super‑Refractory Status Epilepticus: A Ret‑ rospective Study. CNS Drugs. 2016;30(9):869-76. doi: 10.1007/ s40263-016-0371-2. 17. Holtkamp M. Pharmacotherapy for Refractory and Super ‑Refractory Status Epilepticus in Adults. Drugs. 2018;78(3):307326. doi: 10.1007/s40265-017-0859-1. 18. Chin RF, Neville BG, Peckham C, et al. Treatment of community‑onset, childhood convulsive status epilepti‑ cus: a prospective, population‑based study. Lancet Neurol. 2008;7:696-703. doi: 10.1016/S1474-4422(08)70141-8. 19. Katz JB, Owusu K, Nussbaum I, et al. Pearls and Pitfalls of Introducing Ketogenic Diet in Adult Status Epilepticus: A Prac‑ tical Guide for the Intensivist. J Clin Med. 2021;10(4):881. doi: 10.3390/jcm10040881. 20. Katzell L, Beydler EM, Holbert R, et al. Electroconvulsive therapy use for refractory status epilepticus in an implan‑ table vagus nerve stimulation patient: A case report. Front Psychiatry. 2023;14:1126956. doi: 10.3389/fpsyt.2023.1126956. 21. Kellinghaus C, Rossetti AO, Trinka E, et al. Factors predic‑ ting cessation of status epilepticus in clinical practice: data from a prospective observational registry (SENSE). Ann Neurol. 2019;85(3):421-432. doi: 10.1002/ana.25416. 22. Kofke WA, Young RS, Davis P, et al. Isoflurane for refractory status epilepticus: a clinical series. Anesthesiology. 1989;71:653–659. doi: 10.1097/00000542-198911000-00005. 23. Kohrmann M, Huttner HB, Gotthardt D, et al. CSF‑air ‑exchange for pharmacorefractory status epilepticus. J Neurol. 2006;253:1100–1101. doi: 10.1007/s00415-006-0181-4. 24. Lambrecq V, Villéga F, Marchal C, et al. Refractory status epilepticus: electroconvulsive therapy as a possible thera‑ peutic strategy. Seizure. 2012;21(9):661-4. doi: 10.1016/j.sei‑ zure.2012. 07. 010. 25. Legriel S. Hypothermia as a treatment in status epilepti‑ cus: A narrative review. Epilepsy Behav. 2019;101(Pt B):106298. doi: 10.1016/j.yebeh.2019. 04. 051. 26. Marchi NA, Novy J, Faouzi M, et al. Status epilepticus: impact of therapeutic coma on outcome. Critic Care Med. 2015;43(5):1003–1009. doi: 10.1097/CCM.0000000000000881. 27. Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors, and impact on out‑ come. Arch Neurol. 2002;59(2):205-10. doi: 10.1001/archne‑ ur.59. 2. 205. 28. McGinity M, Andrade N, Karkar K, et al. Functional hemispherectomy for refractory status epilepticus in 2 adults. World Neurosurg. 2016;93:e411-486. doi: 10.1016/j. wneu.2016. 06. 086. 29. McHugh P. Acute choreoathetoid reaction to propo‑ fol. Anaesthesia. 1991;46: 425. doi: 10.1111/j.1365-2044.1991. tb09583.x. 30. Mulhofer WG, Layfield S, Lowenstein D, et al. Duration of therapeutic coma and outcome of refractory status epi‑ lepticus. Epilepsia. 2019;60(3):921-934. doi: 10.1111/epi.14706. 31. Mirsattari SM, Sharpe MD, Young GB. Treatment of refractory status epilepticus with inhalational ane‑ sthetic agents isoflurane and desflurane. Arch Neurol. 2004;61(8):1254-1259. doi: 10.1001/archneur.61. 8. 1254. 32. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51(2):251–256. doi: 10.1111/j.1528-1167.2009.02323.x. 33. Oderiz CC, Aberastury M, Besocke AG, et al. Surgical treatment of focal symptomatic refractory status epilepti‑ cus with and without invasive EEG. Epilepsy Behav Case Rep. 2015;4:96–98. doi: 10.1016/j.ebcr.2015. 08. 005. 34. Reznik ME, Berger K, Claassen J. Comparison of intra‑ venous anesthetic agents for the treatment of refractory status epilepticus. J Clin Med. 2016;5(5):pii:E54. doi:10.3390/ jcm5050054. 35. Rossetti AO, Lowenstein DH. Management of refracto‑ ry status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011;10(10):922-930. doi: 10.1016/ S1474-4422(11)70187-9. 36. Rossetti AO, Reichhart MD, Schaller MD, et al. Propo‑ fol treatment of refractory status epilepticus: A study of 31 episodes. Epilepsia. 2004;45(7):757-63. doi: 10.1111/j. 0013-9580.2004.01904.x. 37. Rubin DB, Angelini B, Shoukat M, et al. Electrogra‑ phic predictors of successful weaning from anaesthetics in refractory status epilepticus. Brain. 2020;143(4):1143-1157. doi: 10.1093/brain/awaa069. 38. Sabharwal V, Ramsay E, Martinez R, et al. Propofol ‑ketamine combination therapy for effective control of super‑refractory status epilepticus. Epilepsy Behav. 2015;52(Pt A):264-6. doi: 10.1016/j.yebeh.2015. 07. 040. 39. Sanchez Fernandez I, Abend NS, Agadi S, et al. Gaps and opportunities in refractory status epilepticus research in chil‑ dren: A multi‑center approach by the Pediatric Status Epilep‑ ticus Research Group (pSERG). Seizure. 2014;23(2):87-97. doi: 10.1016/j.seizure.2013. 10. 004. 40. San‑Juan D, Dávila‑Rodríguez DO, Jiménez CR, et al. Neu‑ romodulation techniques for status epilepticus: A review. Brain Stimul. 2019;12(4):835-844. doi: 10.1016/j.brs.2019. 04. 005. 41. Shorvon S, Ferlisi M. The treatment of super‑refractory status epilepticus: A critical review of available therapies and a clinical treatment protocol. Brain. 2011;134(Pt 10):2802-18. doi: 10.1093/brain/awr215. 42. Singh RK, Singh R, Stewart A, et al. Intravenous ganaxo‑ lone in pediatric super‑refractory status epilepticus: a sin‑ gle hospital experience. Epilepsy Behav Rep. 2022;20:100567. doi: 10.1016/j.ebr.2022.100567. 43. Singhi S, Murthy A, Singhi P, et al. Continuous mida‑ zolam versus diazepam infusion for refractory convulsi‑ ve status epilepticus. J Child Neurol. 2002;17:106-10. doi: 10.1177/088307380201700203. 44. Singla L, Shah M, Moore‑Hill D, et al. Electroconvulsi‑ ve therapy for super refractory status epilepticus in preg‑ nancy: case report and review of literature. Int J Neurosci. 2023;133(10):1109-1119. doi: 10.1080/00207454.2022.2050371. 45. Sobstyl M, Stapińska‑Syniec A, Rylski M. Deep brain stimulation for the treatment of refractory and super ‑refractory status epilepticus. Seizure. 2020 Oct;81:58-62. doi: 10.1016/j.seizure.2020. 07. 022. 46. Sutter R, Marsch S, Fuhr P, et al. Anesthetic drugs in sta‑ tus epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;82(8):656–664. doi: 10.1212/WNL.0000000000000009. 47. Trinka E, Brigo F. Neurostimulation in the treatment of refractory and super‑refractory status epilepticus. Epilepsy Behav. 2019;101(Pt B):106551. doi: 10.1016/j.yebeh.2019.106551. 48. Trinka E, Leitinger M. Management of Status Epilepticus, Refractory Status Epilepticus, and Super‑refractory Status Epi‑ lepticus. Continuum (Minneap Minn). 2022 1;28(2):559-602. doi: 10.1212/CON.0000000000001103. 49. Vasquez A, Farias‑Moeller R, Tatum W. Pediatric refractory and super‑refractory status epilepticus. Seizure. 2019 May;68:6271. doi: 10.1016/j.seizure.2018. 05. 012. 50. Vossler DG, Bainbridge JL, Boggs JG, et al. Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Re‑ view by the American Epilepsy Society Treatments Committee. Epilepsy Curr. 2020;20(5):245-264. doi: 10.1177/1535759720928269. 51. Woodward MR, Doddi S, Marano C, et al. Evaluating salvage electroconvulsive therapy for the treatment of prolonged su‑ per refractory status epilepticus: A case series. Epilepsy Behav. 2023;144:109286. doi: 10.1016/j.yebeh.2023.109286. 52. Yeoman P, Hutchinson A, Byrne A, et al. Etomidate infu‑ sions for the control of refractory status epilepticus. Intensive Care Med. 1989;15(4):255-259. doi: 10.1007/BF00271062. 53. Zeiler FA, Zeiler KJ, Teitelbaum J, et al. VNS for refractory status epilepticus. Epilepsy Res. 2015;112:100-13. doi: 10.1016/j. eplepsyres.2015. 02. 014.
RkJQdWJsaXNoZXIy NDA4Mjc=